Similar articles

• Somatostatin receptor-based imaging in malignant lymphomas.

  O'Brien JP. O'Brien JP. J Nucl Med. 1995 Jan;36(1):19-20. J Nucl Med. 1995. PMID: 7799074 No abstract available.
• Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy.

  Lipp RW, Silly H, Ranner G, Dobnig H, Passath A, Leb G, Krejs GJ. Lipp RW, et al. J Nucl Med. 1995 Jan;36(1):13-8. J Nucl Med. 1995. PMID: 7799065 Clinical Trial.
• Somatostatin receptor scintigraphy in malignant lymphoma: first results and comparison with glucose metabolism measured by positron-emission tomography.

  Bares R, Galonska P, Dempke W, Handt S, Büll U, Osieka R. Bares R, et al. Horm Metab Res Suppl. 1993;27:56-8. Horm Metab Res Suppl. 1993. PMID: 8330873
• Somatostatin-receptor imaging in lymphoma.

  Goldsmith SJ, Macapinlac HA, O'Brien JP. Goldsmith SJ, et al. Semin Nucl Med. 1995 Jul;25(3):262-71. doi: 10.1016/s0001-2998(95)80015-8. Semin Nucl Med. 1995. PMID: 7570045 Review.
• Clinical implications of somatostatin-receptor scintigraphy in ophthalmic Graves' disease.

  Colao A, Pivonello R, Lastoria S, Faggiano A, Ferone D, Lombardi G, Fenzi G. Colao A, et al. Eur J Endocrinol. 2000 Oct;143 Suppl 1:S35-42. doi: 10.1530/eje.0.143s035. Eur J Endocrinol. 2000. PMID: 11068938 Review. No abstract available.